Follow
laura esserman
laura esserman
Professor of Surgery and Radiology, University of California, San Francisco
Verified email at ucsf.edu
Title
Cited by
Cited by
Year
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
K Chin, S DeVries, J Fridlyand, PT Spellman, R Roydasgupta, WL Kuo, ...
Cancer cell 10 (6), 529-541, 2006
14902006
Whole-genome analysis informs breast cancer response to aromatase inhibition
MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353-360, 2012
11942012
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A …
JS Vaidya, F Wenz, M Bulsara, JS Tobias, DJ Joseph, M Keshtgar, ...
The Lancet 383 (9917), 603-613, 2014
9352014
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
JS Vaidya, DJ Joseph, JS Tobias, M Bulsara, F Wenz, C Saunders, ...
The Lancet 376 (9735), 91-102, 2010
9032010
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
JL Khatcheressian, P Hurley, E Bantug, LJ Esserman, E Grunfeld, ...
7052012
Rethinking screening for breast cancer and prostate cancer
L Esserman, Y Shieh, I Thompson
Jama 302 (15), 1685-1692, 2009
6902009
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer …
MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ...
Journal of clinical oncology 29 (17), 2342, 2011
6472011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ...
Jama 305 (18), 1873-1881, 2011
6402011
Overdiagnosis and overtreatment in cancer: an opportunity for improvement
LJ Esserman, IM Thompson, B Reid
Jama 310 (8), 797-798, 2013
6062013
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
5782016
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
LJ Esserman, IM Thompson, B Reid, P Nelson, DF Ransohoff, HG Welch, ...
The lancet oncology 15 (6), e234-e242, 2014
5672014
Leukocyte composition of human breast cancer
B Ruffell, A Au, HS Rugo, LJ Esserman, ES Hwang, LM Coussens
Proceedings of the National Academy of Sciences 109 (8), 2796-2801, 2012
5482012
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively …
R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ...
JAMA oncology 6 (5), 676-684, 2020
5182020
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging
L Esserman, N Hylton, L Yassa, J Barclay, S Frankel, E Sickles
Journal of clinical oncology 17 (1), 110-110, 1999
5151999
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL
NM Hylton, JD Blume, WK Bernreuter, ED Pisano, MA Rosen, EA Morris, ...
Radiology 263 (3), 663-672, 2012
5112012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, ...
Journal of Clinical Oncology 30 (26), 3242, 2012
4892012
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy
SC Partridge, JE Gibbs, Y Lu, LJ Esserman, D Sudilovsky, NM Hylton
American Journal of Roentgenology 179 (5), 1193-1199, 2002
4142002
Breast cancer growth prevention by statins
MJ Campbell, LJ Esserman, Y Zhou, M Shoemaker, M Lobo, E Borman, ...
Cancer research 66 (17), 8707-8714, 2006
4082006
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
D Horiuchi, L Kusdra, NE Huskey, S Chandriani, ME Lenburg, ...
Journal of Experimental Medicine 209 (4), 679-696, 2012
3822012
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132, 1049-1062, 2012
3712012
The system can't perform the operation now. Try again later.
Articles 1–20